title: Prevalence and factors associated with uveitis in spondylarthritis patients in France: results from an observational survey.
abstract: OBJECTIVE
  To accurately estimate the prevalence of and the factors associated with uveitis in spondylarthritis (SpA) patients in France.
  
  
  METHODS
  In an observational survey of SpA patients (diagnosis confirmed by the European Spondylarthropathy Study Group and/or Amor's criteria) consulting their rheumatologist for routine followup, we collected information regarding present/past history of uveitis, as well as detailed characteristics of the disease. Factors independently associated with uveitis were determined.
  
  
  RESULTS
  From September 2008 to January 2009, 202 rheumatologists participated in the survey and recruited 902 patients (61% men) with a mean ± SD age of 45.3 ± 13.4 years and a mean ± SD disease duration of 10.4 ± 9.6 years. The SpA diagnoses were ankylosing spondylitis (71%), psoriatic arthritis (18%), or other SpA (11%). The HLA-B27 positivity rate was 76%. Uveitis prevalence was 32.2% (95% confidence interval [95% CI] 29.1-35.3%) since psoriasis and inflammatory bowel disease were 22.3% (95% CI 19.5-25.0%) and 8.6% (95% CI 6.7-10.5%), respectively. Recurrence of uveitis occurred in 52.3% and complications occurred in 11.7% of patients. Factors independently associated with uveitis were HLA-B27 positivity (adjusted odds ratio [OR(adj) ] 2.97 [95% CI 1.83-4.81], P < 0.0001) and disease duration (OR(adj)  1.28 [95% CI 1.16-1.41], P < 0.0001 for ≥10 years).
  
  
  CONCLUSIONS
  Results indicate that uveitis is the most common extraarticular feature of SpA, occurring preferentially in HLA-B27-positive patients over the entire course of the disease.
authors.affiliation: Université Paris Est Créteil and APHP, Hôpital Henri-Mondor, Créteil, France.
authors.forename: F
authors.initials: F
authors.lastname: Canouï-Poitrine
authors.forename: F Kemta
authors.initials: FK
authors.lastname: Lekpa
authors.forename: V
authors.initials: V
authors.lastname: Farrenq
authors.forename: V
authors.initials: V
authors.lastname: Boissinot
authors.forename: C
authors.initials: C
authors.lastname: Hacquard-Bouder
authors.forename: D
authors.initials: D
authors.lastname: Comet
authors.forename: S
authors.initials: S
authors.lastname: Bastuji-Garin
authors.forename: E
authors.initials: E
authors.lastname: Thibout
authors.forename: P
authors.initials: P
authors.lastname: Claudepierre
mesh_terms: D000328:Adult; D015535:Arthritis, Psoriatic / Q000453:epidemiology* / Q000276:immunology; D015897:Comorbidity; D005260:Female; D005602:France / Q000453:epidemiology; D015796:HLA-B27 Antigen / Q000097:blood; D006306:Health Surveys; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000453:epidemiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D025241:Spondylarthritis / Q000453:epidemiology* / Q000276:immunology; D014605:Uveitis / Q000453:epidemiology* / Q000276:immunology
chemical_list: D015796:HLA-B27 Antigen